[1] 吴 珍,杜士明,董永成.纳米粒作为脑靶向给药系统的研究进展[J].中国药房,2007,18(13):1029-1031.
[2] Pardridge WM.Blood-brain barrier drug targeting:the future of brain drug development[J].Mol Interv,2003,3(2):90-105.
[3] Overmoyer B,Silverman P,Holder LW,et al.Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer[J].Clin Breast Cancer,2005,6(2):150-157.
[4] Vorobiof DA, Rapoport BL,Chasen MR,et al.First line therapy with paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) in patients with metastatic breast cancer:a multicentre phase II study[J].Breast,2004,13(3):219-226.
[5] Boulikas T.Clinical overview on lipoplatin:a successful liposomal formulation of cisplatin[J].Expert Opin Investig Drugs,2009,18(8):1197-1218.
[6] Gentile E,Cilurzo F,Marzio LD,et al.Liposomal chemotherapeutics[J].Future Oncol,2013,9(12):1849-1859.
[7] 陆 彬. 新型给药系统聚合物泡囊及其研究进展(上)[J].中国药师,2009,12(4):439-442,446.
[8] Cheng JJ,Teply BA,Sherifi I,et al.Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery[J].Biomaterials,2007,28(5):869-876.
[9] Zhang PC,Hu LJ,Yin Q,et al.Transferrin-modified c[RGDfK]-paclitaxel loaded hybrid micelle for sequential blood-brain barrier penetration and glioma targeting therapy[J].Mol Pharm,2012,9(6):1590-1598.
[10] Kwon EJ,Lasiene J,Jacobson BE,et al.Targeted nonviral delivery vehicles to neural progenitor cells in the mouse subventricularzone[J].Biomaterials,2010,31(8):2417-2424.